CMC(SH:603122) Sou Hu Cai Jing·2025-05-27 10:45Group 1 - The core viewpoint of the articles highlights the financial performance and market position of HeFu China, particularly its high PE ratio compared to industry averages [1][2] - As of May 27, HeFu China's closing price was 6.78 yuan, with a PE ratio of 187.01, significantly higher than the industry average of 42.04 and median of 28.02 [1][2] - The total market capitalization of HeFu China is reported at 2.699 billion yuan [1][2] Group 2 - HeFu China's main business involves international trade and after-sales services related to in vitro diagnostic medical devices and consumables, as well as consulting services for hospital information management systems [1] - The latest quarterly report for Q1 2025 shows HeFu China achieved a revenue of 176 million yuan, representing a year-on-year decrease of 26.35%, and a net loss of approximately 6 million yuan, a decline of 184.13% [1] - The gross profit margin for the company stands at 16.71% [1] Group 3 - As of March 31, 2025, HeFu China had 33,527 shareholders, a decrease of 3,450 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]